These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1715225)

  • 21. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.
    Przepiorka D; LeMaistre CF; Huh YO; Luna M; Saria EA; Brown CT; Champlin RE
    Ther Immunol; 1994 Apr; 1(2):77-82. PubMed ID: 7584486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation.
    Champlin R
    Hematol Oncol Clin North Am; 1990 Jun; 4(3):687-98. PubMed ID: 2193019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective depletion of CD8 positive T-lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation.
    Champlin R; Gajewski J; Feig S; Giorgi J; Lyddane N; Lee K; Schmidt I; Winston D; Ho W; Reichert T
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2947-8. PubMed ID: 2495694
    [No Abstract]   [Full Text] [Related]  

  • 24. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
    Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
    Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depletion of T-lymphocytes in donor marrow with pan-T monoclonal antibodies and complement for prevention of acute graft-versus-host disease: a pilot study on 29 patients.
    Herve P
    J Natl Cancer Inst; 1986 Jun; 76(6):1311-6. PubMed ID: 3520074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of monoclonal antibodies in vivo as a therapeutic strategy for acute GvHD in matched and mismatched bone marrow transplantation.
    Herve P; Bordigoni P; Cahn JY; Flesch M; Tiberghien P; Racadot E; Milpied N; Bergerat JP; Plouvier E; Roche C
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1692-4. PubMed ID: 1989333
    [No Abstract]   [Full Text] [Related]  

  • 27. T-cell depletion with the monoclonal antibody Campath 1 to prevent graft-versus-host disease in ten high-risk adult patients.
    Bandini G; Ricci P; Gobbi M; Tazzari PL; Motta MR; Guardigli C; Rizzi S; Baccarani M; Tura S
    Haematologica; 1986; 71(4):307-11. PubMed ID: 3096824
    [No Abstract]   [Full Text] [Related]  

  • 28. The use of monoclonal antibodies in graft versus host disease prevention.
    Brenner MK; Grob JP; Prentice HG
    Haematologia (Budap); 1986; 19(3):167-76. PubMed ID: 3536685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T cell depletion of HLA and haploidentical marrow reduces graft-versus-host disease but it may impair a graft-versus-leukemia effect.
    Henslee PJ; Thompson JS; Romond EH; Doukas MA; Metcalfe M; Marshall ME; MacDonald JS
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2701-6. PubMed ID: 3547948
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of steroid-resistant acute graft-vs-host disease after allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT563).
    Hertenstein B; Stefanic M; Sandherr M; Bunjes D; Mertens T; Arnold R
    Transplant Proc; 1994 Dec; 26(6):3114-6. PubMed ID: 7998086
    [No Abstract]   [Full Text] [Related]  

  • 31. [Antonio Raichs lecture. Graft versus host disease and the graft-against-leukemia reaction. Memorial lecture].
    Rozman C
    Sangre (Barc); 1990 Dec; 35(6):465-73. PubMed ID: 2087666
    [No Abstract]   [Full Text] [Related]  

  • 32. Results of four different protocols for prophylaxis against graft-versus-host disease.
    Tollemar J; Ringdén O; Bäckman L; Janossy G; Lönnqvist B; Markling L; Philstedt P; Sundberg B
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3008-10. PubMed ID: 2650414
    [No Abstract]   [Full Text] [Related]  

  • 33. Prevention of graft-versus-host disease by lymphocyte depletion of the bone marrow graft with use of counterflow centrifugation.
    Haanen C; De Witte T; Plas A; Schattemberg T
    Haematologica; 1991 Mar; 76 Suppl 1():22-8. PubMed ID: 1864551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
    Kohler PC; Erickson C; Finlay JL; Trigg ME; Edwards B; Hong R; Hank JA; Billing R; Bozdech M; Sondel PM
    Cancer Res; 1986 Oct; 46(10):5413-8. PubMed ID: 3530439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone marrow transplantation for severe aplastic anaemia: cost/benefit of increased immunosuppression.
    Gordon-Smith EC
    Bone Marrow Transplant; 1991; 7 Suppl 2():103-5. PubMed ID: 1908725
    [No Abstract]   [Full Text] [Related]  

  • 36. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.
    Apperley JF; Jones L; Hale G; Waldmann H; Hows J; Rombos Y; Tsatalas C; Marcus RE; Goolden AW; Gordon-Smith EC
    Bone Marrow Transplant; 1986 May; 1(1):53-66. PubMed ID: 3332120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laboratory control in predicting clinical efficacy of T cell-depletion procedures used for prevention of graft-versus-host disease: importance of limiting dilution analysis.
    Marciniak E; Romond EH; Thompson JS; Henslee PJ
    Bone Marrow Transplant; 1988 Nov; 3(6):589-98. PubMed ID: 3063328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prevention and treatment of acute graft-versus host disease].
    Hervé P
    Presse Med; 1991 Oct; 20(33):1614-21. PubMed ID: 1835077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-cell depletion in allogeneic bone marrow transplantation for acute leukaemias.
    Aversa F; Terenzi A; Carotti A; Velardi A; Latini P; Gambelunghe C; Grignani F; Martelli MF
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():69-72. PubMed ID: 2697440
    [No Abstract]   [Full Text] [Related]  

  • 40. Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients.
    Blaise D; Olive D; Hirn M; Viens P; Lafage M; Attal M; Stoppa AM; Gabert J; Gastaut JA; Camerlo J
    Bone Marrow Transplant; 1991 Aug; 8(2):105-11. PubMed ID: 1933050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.